Compare Gilead Sciences, Inc. (GILD) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Snap Inc — how do they compare? Gilead Sciences, Inc. trades at $135.26 (market cap $164.99B), while Snap Inc trades at $5.51 (market cap $9.05B). The key difference: Gilead Sciences, Inc. is far larger — about 18.2× Snap Inc's market cap, and Gilead Sciences, Inc. pays a 2.47% dividend while Snap Inc pays none. Which is the better fit depends on your goals.
| GILD | SNAP | |
|---|---|---|
Market Cap | $164.99B | $9.05B |
Sector | Health | Media |
52-Week High | $155.80 | $9.09 |
52-Week Low | $110.56 | $3.93 |
Enterprise Value | $188.06B | $10.61B |
Dividend Yield | 2.47% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
